Professor Paul Pavli AM

MB, BS (Hons), PhD, FRACP
Sub Dean Canberra Hospital campus, ANU Medical School
Gastroenterology & Hepatology Staff Specialist, Canberra Hospital

Paul Pavli trained in Gastroenterology at Concord and Royal North Shore Hospitals in Sydney and has had an ongoing interest in the basic science and clinical aspects of the inflammatory bowel diseases (IBD) since he finished his specialist training.  He completed a PhD in gastrointestinal immunology at the Australian National University (ANU) and has pursued an active research program studying the causes of IBD.  Working with researchers from the ANU, he helped establish the Australian Familial IBD Register in the early 1990s, and more recently, has been studying the role of bacteria in triggering IBD.

In parallel he has helped develop a clinical service in IBD at Canberra Hospital where patients have access to all facets of treatment including clinical trials of novel therapies and nursing, surgical, nutritional and psychological support for patients and their families.

Paul has maintained an active role as a teacher and mentor for undergraduate medical students, hospital resident staff and advanced trainees in Gastroenterology who wish to specialise in the management of IBD.

Paul has also served on a number of Federal and Territory government bodies and professional organizations including the Australian Drug Evaluation Committee (ADEC), now the Advisory Committee on Pharmaceutical Medicines (ACPM), the National Health and Medical Research Council (NHMRC), the Royal Australasian College of Physicians, the Gastroenterological Society of Australia and Therapeutic Guidelines.

Specialisation

  • Gastroenterology
  • Hepatpology
  • Dixit, O, O'Brien, C, Pavli, P et al 2018, 'Withinâ€?host evolution versus immigration as a determinant of Escherichia coli diversity in the human gastrointestinal tract', Environmental Microbiology, vol. 20, no. 3, pp. 993-1001pp.
  • Chan, W, Lynch, N, Bampton, P et al 2018, 'Entyvio lengthen dose-interval study: Lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease', European Journal of Gastroenterology and Hepatology, vol. 30, no. 7, pp. 735-740.
  • Keightley, P, Reay, R, Pavli, P et al 2018, 'Inflammatory bowel disease-related fatigue is correlated with depression and gender', Australasian Psychiatry, vol. 26, no. 5, pp. 1-6.
  • Dederichs, F, Lesalnieks, I, Sladek, M et al 2018, 'Genital granulomatosis in Crohn's disease: results of the ECCO CONFER study', 13th Congress of the European Crohn’s and Colitis Organisation, Oxford University Press, United Kingdom, pp. S84-S85.
  • Dederichs, F, Lesalnieks, I, Sladek, M et al 2018, 'Genital granulomatosis in male and female patients with Crohn's disease: Clinical presentation and treatment outcomes', Journal of Crohn's and Colitis, vol. 12, no. 2, pp. 197-203.
  • O'Brien, C, Kiely, C & Pavli, P 2018, 'The microbiome of Crohn's disease aphthous ulcers 06 Biological Sciences 0605 Microbiology', Gut Pathogens, vol. 10, no. 44, pp. 8pp.
  • Baut, G, O'Brien, C, Pavli, P et al 2018, 'Prevalence of YersiniaSpecies in the Ileum of Crohn's Disease Patients and Controls', Frontiers in Cellular and Infection Microbiology, vol. 8, no. 336, pp. 1-9pp.
  • Kiely, C, Pavli, P & O'Brien, C 2018, 'The role of inflammation in temporal shifts in the inflammatory bowel disease mucosal microbiome', Gut Microbes, vol. 9, no. 6, pp. 477-485pp.
  • Kiely, C, Pavli, P & O'Brien, C 2018, 'The microbiome of translocated bacterial populations in patients with and without inflammatory bowel disease', Internal Medicine Journal, vol. 48, no. 11, pp. 1346-1354pp.
  • Baillie, J, Arner, E, Daub, C et al 2017, 'Analysis of the human monocyte-derived macrophage transcriptome and response to lipopolysaccharide provides new insights into genetic aetiology of inflammatory bowel disease', PLoS Genetics, vol. 13, no. 3, pp. 1-36.
  • O'Brien, C, Patel, H, Freeman, T et al. 2017, 'Gene expression differences between Crohn's disease aphthous ulcers and healthy Peyer's patches highlight novel therapeutic targets', Gastroenterological Society of Australia Australian Gastroenterology Week Precision Medicine in Gastroenterology, 2017, John Wiley & Sons Ltd., Australia, pp. 119-119.
  • Holt, N, Pavli, P & Subramaniam, K 2017, 'Quality of life in patients with ulcerative colitis', Gastroenterological Society of Australia Australian Gastroenterology Week Precision Medicine in Gastroenterology, 2017, John Wiley & Sons Ltd., Australia, pp. Volume: 32, Supplement: 2, Page: 128.
  • Subramaniam, K, Tweedale, M & Pavli, P 2017, 'Intra-abdominal collections in Crohn's disease: outcomes following anti-TNF therapy', 12th Congress of European Crohn's and Colitis Organisation, ECCO 2017, ed. Laurence J Egan, Oxford University Press, United Kingdom, pp. Supplement: 1, Abstract: P673, Page: S424.
  • Kiely, C, Pavli, P & O'Brien, C 2017, 'Inflammation and changes in the inflammatory bowel disease microbiome over time', Gastroenterological Society of Australia Australian Gastroenterology Week Precision Medicine in Gastroenterology, 2017, John Wiley & Sons Ltd., Australia, pp. 118-118.
  • Wark, K, Pavli, P & Subramaniam, K 2017, 'A retrospective case series of the use of ustekinumab in patients with inflammatory bowel disease at an Australian tertiary referral center', Gastroenterological Society of Australia Australian Gastroenterology Week Precision Medicine in Gastroenterology, 2017, John Wiley & Sons Ltd., Australia, pp. 151-152.
  • O'Brien, C, Patel, H, Freeman, T et al. 2017, 'Gene expression differences between Crohn's disease aphthous ulcers and healthy Peyer's patches highlights potential treatment strategies [meeting abstract]', 12th Congress of European Crohn's and Colitis Organisation, ECCO 2017, ed. Laurence J Egan, Oxford University Press, United Kingdom, pp. S470-S470.
  • Subramaniam, K, Watthayalage, R, Neeman, T et al. 2017, 'Is anti-TNF therapeutic drug monitoring of value in IBD patients in clinical remission?', 12th Congress of European Crohn's and Colitis Organisation, ECCO 2017, ed. Laurence J Egan, Oxford University Press, United Kingdom, pp. Supplement: 1, Page: S353, Abstract: P537.
  • Kiely, C, Pavli, P & O'Brien, C 2017, 'Bacterial RNA in lymph nodes of patients with inflammatory bowel disease', Gastroenterological Society of Australia Australian Gastroenterology Week Precision Medicine in Gastroenterology, 2017, John Wiley & Sons Ltd., Australia, pp. 118-119.
  • Tai, J, Pavli, P & Subramaniam, K 2017, 'Ten-year outcomes of anti-tumor necrosis factor therapy in inpatients with inflammatory bowel disease', Gastroenterological Society of Australia Australian Gastroenterology Week Precision Medicine in Gastroenterology, 2017, John Wiley & Sons Ltd., Australia, pp. Volume: 32. Supplement: 2, Page: 148.
  • Peer, F, Miller, A, Pavli, P et al 2017, 'Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients', Internal Medicine Journal, vol. 47, no. 12, pp. 1445-1448pp.
  • O'Brien, C, Bringer, M, Holt, K et al 2017, 'Comparative genomics of Crohn's disease-associated adherent-invasive Escherichia coli', Gut, vol. 66, no. 8, pp. 1382-1389.
  • Gordon, D, Geyik, S, Clermont, O et al 2017, 'Fine-Scale Structure Analysis Shows Epidemic Patterns of Clonal Complex 95, a Cosmopolitan Escherichia coli Lineage Responsible for Extraintestinal Infection', mSphere, vol. 2, no. 3, pp. 15pp..
  • Kiely, C, Subramaniam, K, Platten, J et al 2016, 'Safe and effective: Anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis', Internal Medicine Journal, vol. 46, no. 5, pp. 616-619.
  • Chen, G, Crispin, P, Cherian, M et al 2016, 'Placental involvement by non-Hodgkin lymphoma in a Crohn disease patient on long-term thiopurine therapy', Internal Medicine Journal, vol. 46, no. 1, pp. 102-105.
  • Chen, G, Crispin, P, Cherian, M et al 2016, 'Placental involvement by non-Hodgkin lymphoma in a Crohn disease patient on long-term thiopurine therapy', Internal Medicine Journal, vol. 46, no. 1, pp. 102-105.
  • Vennonen, I, O'Brien, C, Pavli, P et al 2016, 'Reactivity of monocyte-derived macrophages from patients with Crohn's disease', Gastroenterological Society of Australia, Australian Gastroenterology Week 2016, Wiley-Blackwell Publishing Asia, Australia, pp. 126-126.
  • O'Brien, C, Gordon, D & Pavli, P 2016, 'Microbial communities of Crohn's disease aphtous ulcers', 11th Annual Congress of the European Crohn's and Colitis Organisation (ECCO), Oxford University Press, United Kingdom, pp. S488-S489.
  • O'Brien, C, Gordon, D & Pavli, P 2016, 'Higher frequency of adherent-invasive Escherichia coli within a sub- group of B2 phylogroup strains', 11th Annual Congress of the European Crohn's and Colitis Organisation (ECCO), Oxford University Press, United Kingdom, pp. S489-S490.
  • Subramaniam, K, Tymms, K, Shadbolt, F et al 2015, 'Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors', Internal Medical Journal, vol. 45, no. 11, pp. 1154-1160.
  • Subramaniam, K, Fallon, K, Ruut, T et al 2015, 'Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease', Alimentary pharmacology & therapeutics, vol. 41, no. 5, pp. 419-428.
  • Gordon, D, O'Brien, C & Pavli, P 2015, 'Escherichia coli diversity in the lower intestinal tract of humans', Environmental Microbiology Reports, vol. 7, no. 4, pp. 642-648.
  • Leu, A, Pavli, P, Gordon, D et al 2015, 'Relative abundance of Mycobacterium in ovine Johne's disease', Microbiology Australia, vol. 36, no. 1, pp. 32-36.
  • Keightley, P, Pavli, P, Platten, J et al 2015, 'Gut feelings 2. Mind, mood and gut in inflammatory bowel disease: Approaches to psychiatric care', Australasian Psychiatry, vol. 23, no. 4, pp. 407-410.
  • Keightley, P, Pavli, P, Platten, J et al 2015, 'Gut feelings 1. Mind, mood and gut in irritable bowel syndrome: Approaches to psychiatric care', Australasian Psychiatry, vol. 23, no. 4, pp. 403-406.
  • Subramaniam, K, Richardson, A, Dodd, J et al 2014, 'Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy', Internal Medicine Journal, vol. 44, no. 5, pp. 464-470.
  • Subramaniam, K, Yeung, D, Grimpen, F et al 2014, 'Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?', Internal Medicine Journal, vol. 44, no. 3, pp. 287-290.
  • Subramaniam, K, Fallon, K, Ruut, T et al 2014, 'Mo1249 The Anti-TNF Agent Infliximab Reverses Inflammatory Sarcopenia in Crohn's Disease', Gastroenterology, vol. 146, no. 5, pp. S597-S597.
  • Kiely, C & Pavli, P 2014, 'Clostridium difficile diarrhoea: a side effect of health care', Medicine Today, vol. 15, no. 11, pp. 61-63.
  • O'Brien, C, Pavli, P, Gordon, D et al 2014, 'Detection of bacterial DNA in lymph nodes of Crohn's disease patients using high throughput sequencing', Gut, vol. 63, no. 10, pp. 1596-1606.
  • Subramaniam, K, Hughes, A & Pavli, P 2013, 'Foot Drop Developing During Infliximab Therapy for Inflammatory Bowel Disease', Inflammatory Bowel Diseases, vol. 19, no. 2, pp. E24-E25.
  • O'Brien, C, Allison, G, Grimpen, F et al 2013, 'Impact of Colonoscopy Bowel Preparation on Intestinal Microbiota', PLOS ONE (Public Library of Science), vol. 8, no. 5.
  • Subramaniam, K, Cherian, M, Jain, S et al 2013, 'Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications', Internal Medicine Journal, vol. 43, no. 12, pp. 1339-1342.
  • Subramaniam, K, D'Rozario, J & Pavli, P 2013, 'Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: A review', Journal of Gastroenterology and Hepatology, vol. 28, no. 1, pp. 24-30.
  • O'Brien, C, Allison, G & Pavli, P 2013, 'The more the merrier: Faecalibacterium prausnitzii in Crohn's disease', Journal of Gastroenterology and Hepatology, vol. 28, no. 5, pp. 757-759.
  • Sandborn, W, Feagan, B, Rutgeerts, P et al 2013, 'Vedolizumab as induction and maintenance therapy for Crohn's disease', New England Journal of Medicine, vol. 369, no. 8, pp. 711-721.
  • Feagan, B, Rutgeerts, P, Sands, B et al 2013, 'Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis', New England Journal of Medicine, vol. 369, no. 8, pp. 699-710.
  • Subramaniam, K & Pavli, P 2012, 'Risk of non-melanoma skin cancer with thiopurine use in inflammatory bowel disease', Journal of Gastroenterology and Hepatology, vol. 27, no. 2, pp. 193-194.
  • Subramaniam, K, Pavli, P, Llewellyn, H et al 2012, 'Glatiramer acetate induced hepatotoxicity', Current Drug Safety, vol. 7, no. 2, pp. 186-188.
  • Subramaniam, K, Chitturi, S, Brown, M et al 2011, 'Infliximab-induced Autoimmune Hepatitis in Crohn's Disease Treated with Budesonide and Mycophenolate', Inflammatory Bowel Diseases, vol. 17, no. 11, pp. E149-E150.
  • Tyrer, P, Bean, E, Foxwell, A et al 2011, 'Effects of bacterial products on enterocyte-macrophage interactions in vitro', Biochemical and Biophysical Research Communications, vol. 413, no. 2, pp. 336-341.
  • Subramaniam, K, Tucker, K, Craft, P et al 2011, 'Should Patients Be Screened for Hereditary Cancer Syndromes Before Starting Anti-TNF alpha Therapy?', Inflammatory Bowel Diseases, vol. 17, no. 11, pp. e151-e152.
  • Grimpen, F & Pavli, P 2010, 'Advances in the management of inflammatory bowel disease', Internal Medicine Journal, vol. 40, no. 4, pp. 258-264.
  • Thomson, A, Tye-Din, J, Tonga, S et al 2007, 'Aspiration in the context of upper gastrointestinal endoscopy', Canadian Journal of Gastroenterology, vol. 21, no. 4, pp. 223-5.
  • Fisher, L, Fisher, A, Pavli, P et al 2007, 'Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention', Alimentary pharmacology & therapeutics, vol. 25, no. 3, pp. 297-308.
  • Pierik, M, Yang, H, Barmada, M et al 2005, 'The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene-environment interaction', Inflammatory Bowel Diseases, vol. 11, no. 1, pp. 1-7.
  • Grimm, M & Pavli, P 2004, 'NOD2 mutations and Crohns Disease: are Paneth cells and their antimicrobial peptides the link?', Gut, vol. 53, pp. 1558-1560.
  • Stevceva, L, Pavli, P, Husband, A et al 2001, 'The inflammatory infiltrate in the acute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it', BMC Clinical Pathology, vol. 1, no. 3.
  • Stevceva, L, Pavli, P, Husband, A et al 2001, 'Dextran sulphate sodium-induced colitis is ameliorated in interleukin 4 deficient mice', Genes and Immunity, vol. 2, pp. 309-316.
  • Stevceva, L, Pavli, P, Husband, A et al 2000, 'Eosinophilia is attenuated in experimental colitis induced in IL-5 deficient mice', Genes and Immunity, vol. 1, pp. 213-218.
  • Stevceva, L, Pavli, P, Wozniak, A et al 1999, 'Dextran sodium sulphate-induced colitis activity varies with mouse strain but develops in lipopolysaccharide-unresponsive mice', Journal of Gastroenterology and Hepatology, vol. 14, no. 1, pp. 54-60.

Supervised students